# OnCo record stevie (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/stevie/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "stevie", "NCT01367665" ;
  schema:name "STEVIE (vismodegib in ordinary practice)"@en ;
  schema:alternateName "STEVIE"@en, "Safety Events in Vismodegib study"@en ;
  schema:description "This is the study that measured what taking the basal cell carcinoma pill is actually like, in more than a thousand ordinary patients rather than a hundred selected ones. It shrank most tumours. Almost everybody had side effects, and the average person stopped after about eight months."@en ;
  schema:url <https://onco.cc/trials/stevie/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01367665>, <https://doi.org/10.1016/j.ejca.2017.08.022>, <https://pubmed.ncbi.nlm.nih.gov/29073584/> ;
  onco:status "mixed" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/basal-cell-carcinoma/>, <https://onco.cc/cancers/locally-advanced-bcc/>, <https://onco.cc/cancers/skin-cancer/> ;
  onco:technologies <https://onco.cc/technologies/hedgehog-inhibitors/> ;
  onco:targets <https://onco.cc/targets/smoothened/> ;
  onco:drugs <https://onco.cc/drugs/vismodegib/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:pathways <https://onco.cc/pathways/hedgehog/> ;
  onco:terms <https://onco.cc/terms/hedgehog-inhibitor-tolerability/> ;
  onco:trials <https://onco.cc/trials/erivance/>, <https://onco.cc/trials/bolt/>, <https://onco.cc/trials/vismoneo/>, <https://onco.cc/trials/cemiplimab-advanced-bcc/> .